Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CUMBERLAND PHARMACEUTICALS INC
Report date March 17, 2021 · Filed June 11, 2021
Section 16 reporting ended · disclosed 2021-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,720 |
Ending reported balance
After 2021-05-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-03-17 · Tax withholding · Disposed 1,067 · Balance 19,220 F1: This transaction represents shares purchased by the Company to cover the tax withholding obligations for the vesting of shares. Row 2 · 2021-05-17 · Other · Disposed 7,500 · Balance 11,720 F2: Resigned position as Chief Financial Officer effective May 17, 2021. All unvested equity awards forfeited upon resignation. |
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2031-03-17 | Direct | 5,000 |
Reported balance
After 2021-03-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-17 · Grant · Acquired 5,000 · Balance 5,000 F3: 100% vesting on March 17, 2025. |
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2031-03-17 | Direct | 0 |
Reported balance
After 2021-05-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-17 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Resigned position as Chief Financial Officer effective May 17, 2021. All unvested equity awards forfeited upon resignation. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents shares purchased by the Company to cover the tax withholding obligations for the vesting of shares.
F2: Resigned position as Chief Financial Officer effective May 17, 2021. All unvested equity awards forfeited upon resignation.
F3: 100% vesting on March 17, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2021 Filed Jun 11, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Disposition to issuerOptions (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-21-039917 · doc4.xml · derivative · entry 4 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2031-03-17 F2 · shares: Resigned position as Chief Financial Officer effective May 17, 2021. All unvested equity awards forfeited upon resignation. Read SEC document |
| May 17, 2021 Filed Jun 11, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | OtherCommon Stock | 7,500 | $2.83 | $21,225.00 |
DisclosureSEC source: 0001209191-21-039917 · doc4.xml · nonDerivative · entry 2 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,720 F2 · shares: Resigned position as Chief Financial Officer effective May 17, 2021. All unvested equity awards forfeited upon resignation. Read SEC document |
| March 17, 2021 Filed Jun 11, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantOptions (right to buy) · Derivative | 5,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-21-039917 · doc4.xml · derivative · entry 3 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2031-03-17 F3 · shares: 100% vesting on March 17, 2025. Read SEC document |
| March 17, 2021 Filed Jun 11, 2021 21:07 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 1,067 | $3.22 | $3,435.74 |
DisclosureSEC source: 0001209191-21-039917 · doc4.xml · nonDerivative · entry 1 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,220 F1 · shares: This transaction represents shares purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| March 23, 2020 Filed Apr 17, 2020 21:18 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 2,500 | $3.56 | $8,900.00 |
DisclosureSEC source: 0001209191-20-024880 · doc4.xml · nonDerivative · entry 2 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,287 F2 · shares: Restricted stock award will vest 100% on March 23, 2024. Read SEC document |
| March 18, 2020 Filed Apr 17, 2020 21:18 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 2,134 | $3.53 | $7,533.02 |
DisclosureSEC source: 0001209191-20-024880 · doc4.xml · nonDerivative · entry 1 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,787 F1 · shares: This transaction represents shares purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| March 22, 2019 Filed Mar 22, 2019 21:23 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 1,033 | $5.62 | $5,805.46 |
DisclosureSEC source: 0001209191-19-021052 · doc4.xml · nonDerivative · entry 2 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,921 F2 · shares: This transaction represents shares withheld by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| March 22, 2019 Filed Mar 22, 2019 21:23 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 2,500 | $5.98 | $14,950.00 |
DisclosureSEC source: 0001209191-19-021052 · doc4.xml · nonDerivative · entry 1 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,954 F1 · shares: Restricted stock award will vest 100% on March 18, 2023. Read SEC document |
| August 29, 2018 Filed Aug 31, 2018 21:19 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 100 | $6.24 | $624.00 |
DisclosureSEC source: 0001209191-18-049112 · doc4.xml · nonDerivative · entry 2 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,454 Read SEC document |
| August 28, 2018 Filed Aug 31, 2018 21:19 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 300 | $5.92 | $1,776.00 |
DisclosureSEC source: 0001209191-18-049112 · doc4.xml · nonDerivative · entry 1 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,354 Read SEC document |
| May 17, 2018 Filed May 18, 2018 21:11 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 400 | $6.12 | $2,448.00 |
DisclosureSEC source: 0001209191-18-031475 · doc4.xml · nonDerivative · entry 1 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,054 Read SEC document |
| March 23, 2018 Filed Mar 23, 2018 21:40 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 843 | $6.70 | $5,648.10 |
DisclosureSEC source: 0001209191-18-021463 · doc4.xml · nonDerivative · entry 3 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,654 F2 · shares: This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares. Read SEC document |
| March 23, 2018 Filed Mar 23, 2018 21:40 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 2,500 | $6.70 | $16,750.00 |
DisclosureSEC source: 0001209191-18-021463 · doc4.xml · nonDerivative · entry 2 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,497 F1 · shares: Restricted stock award will vest 100% on March 20, 2022. Read SEC document |
| March 19, 2018 Filed Mar 23, 2018 21:40 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 300 | $6.72 | $2,016.00 |
DisclosureSEC source: 0001209191-18-021463 · doc4.xml · nonDerivative · entry 1 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,997 Read SEC document |
| November 22, 2017 Filed Nov 24, 2017 22:15 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 250 | $7.81 | $1,952.50 |
DisclosureSEC source: 0001209191-17-062464 · doc4.xml · nonDerivative · entry 1 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,697 Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 20:57 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 500 | $6.72 | $3,360.00 |
DisclosureSEC source: 0001209191-17-050310 · doc4.xml · nonDerivative · entry 1 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,447 Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 21:21 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 300 | $6.95 | $2,085.00 |
DisclosureSEC source: 0001209191-17-037364 · doc4.xml · nonDerivative · entry 1 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,947 Read SEC document |
| April 07, 2017 Filed Apr 7, 2017 20:52 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | Tax withholdingCommon Stock | 653 | $6.45 | $4,211.85 |
DisclosureSEC source: 0001209191-17-026295 · doc4.xml · nonDerivative · entry 2 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,647 F2 · shares: This transaction represents shares withheld by the Company to cover the tax withholding obligations for the vesting of 2,000 shares during March 2017. Read SEC document |
| April 07, 2017 Filed Apr 7, 2017 20:52 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | GrantCommon Stock | 2,500 | $6.45 | $16,125.00 |
DisclosureSEC source: 0001209191-17-026295 · doc4.xml · nonDerivative · entry 1 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,300 F1 · shares: Restricted stock award will vest 100% on March 17, 2021. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 21:00 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 900 | $6.42 | $5,778.00 |
DisclosureSEC source: 0001209191-17-022787 · doc4.xml · nonDerivative · entry 1 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,800 Read SEC document |
| November 17, 2016 Filed Nov 18, 2016 22:13 UTC | CUMBERLAND PHARMACEUTICALS INC CPIX · Entity 6757 | PurchaseCommon Stock | 900 | $5.50 | $4,950.00 |
DisclosureSEC source: 0001209191-16-151281 · doc4.xml · nonDerivative · entry 1 Bonner Michael · CIK 0001666790 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,900 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.